DOCSLIB.ORG

Endometrial Cancer -Pregnancy -Uterine Or Cervical Polyps Complications -Uterine Leiomyomata -Trauma Risk Factors for Endometrial Cancer (RR = RelaVe Risk)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Endometrial Cancer -Pregnancy -Uterine Or Cervical Polyps Complications -Uterine Leiomyomata -Trauma Risk Factors for Endometrial Cancer (RR = Rela�Ve Risk) Endocrine causes Infections -Cushing’s disease -Chlamidia -Immature hypothalamic- -Gonorrhea pituitary axis -PID -Hyperprolactinemia -Hypothyroidism Medications -Menopause -Obesity -Hormonal agents -PCOD -Low dose OCs CAUSES OF AUB -Premature ovarian failure -IUD (differential -NSAIDs analysis Structural lesions -POP (“mini pill”} and diagnosis) -Tamoxifen -Adenomyosis -Warfarin -Coagulopathies -Condyloma accuminata Pregnancy -Dysplastic or malignant lesions of cervix or vagina -Ectopic pregnancy -Endometriosis -Incomplete abortion -Endometrial cancer -Pregnancy -Uterine or cervical polyps complications -Uterine leiomyomata -Trauma Risk factors for endometrial cancer (RR = relave risk) Age - 75% of cases occur aer menopause RR (age > 60 years) = 5.2 with peak incidence in the late 60s. Obesity - especially upper body fat. This may RR= 3 to 10 be secondary to increased estrogen producon and bioavailability. Polycysc ovary disease. RR = 5.2 Unopposed exogenous estrogen. RR = 2 to 14 When progesns are added (oral contracepves RR= 0.5 to 1 or with replacement therapy), relave risk is less than for the general populaon. Diabetes (all types grouped). Personal or family history of ovarian or breast RR = 2 to 2.8 cancer. Women who are overweight and have had breast cancer are at even greater risk. Nulliparity. RR = 1.3 Late menopause. RR entering menopause aer age 52 = 2.5 Tamoxifen therapy - Use for greater than one year is an independent risk factor. RR = 7.5 Basic FIGO classificaon system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproducve age Polyp Coagulopathy Adenomyosis Ovulatory dysfunction Leiomyoma (submucosal or other) Endometrial Malignancy & hyperplasia Iatrogenic Not yet classified Progesterone Dydrogesterone Tanaproget 17-OH-progesterone 19-norprogesterone derivated derivated PREGNANES NOR-PREGNANES - Hydroxyprogesterone - Nomegestrol acetate ESTRANES GONANES caproate - Demegestone -Lynestrenol -Norgestrel - Hydroxyprogesterone - Promegestone -Levonorgestrel -Desogestrel heptanoate - Nestorone -Norethisterone -Gestodene - Gestonorone caproate - Trimegestone -Norethisterone -Norgestimate - Chlormadinone acetate acetate - Medrogestone -Ethinodiol diacetate - Medroxyprogesterone -Norgestrienone acetate -Dienogest - Cyproterone acetate Drospirenone Hysterectomy remains the most absolutely curative treatment for DUB. Elective hysterectomy has a mortality rate of six per 10,000 operations. One randomized study found that hysterectomy was associated with more morbidity and much longer healing times than endometrial ablation. 12 hysterectomy was associated with more Fortunately,morbidity a and recent much study longer found thathealing sexual times functioning improved overall after hysterectomy than endometrial ablation with an increase in sexual activity and a decrease in problems with sexual functioning. 34 It still remains a popular method of treating DUB, especially in industrialized countries. 1. Neese RE. Abnormal vaginal bleeding in perimenopausal women. Am Fam Physician 1989; 40:185-92. 2. Bayer SR, DeCherney AH. Clinical manifestaons and treatment of dysfunconal uterine bleeding. JAMA 1993; 269:1823-8. 3. Baughan DM. Changes in the management of paents with dysfunconal uterine bleeding. Fam Pract Recerficaon 1993; 15:68-78. 4. Prior JC, Ho Yuen B, Clement P, Bowie L, Thomas J. Reversible luteal phase changes and inferlity associated with marathon training. Lancet 1982; 2:269-70. Endometrial biopsy (EMB) is the most commonly used diagnosc test for DUB. It provides an adequate sample for diagnosis of endometrial problems in 90% to 100% of cases,1,2 but may fail to detect polyps and leiomyomas. It is indicated in all women with DUB who are 35 years of age or older, since their risk of developing malignancy is much higher. Any woman with amenorrhea for one year or longer who experiences uterine bleeding also should have an EMB. The slim endometrial Endometrial biopsy may fail to detect polyps suc3on currees (Pipelleand ) produce samples comparable to older, leiomyomas. more traumac methods but with less pain.3 1. Goldschmit R, Katz Z, Blickstein I, Caspi B, Dgani R. The accuracy of endometrial Pipelle sampling with and without sonographic measurement of endometrial thickness. Obstet Gynecol 1993; 82:727-30. 2. Stovall TG, Ling FW, Morgan PL. A prospecve randomized comparison of the Pipelle endometrial sampling device with the Novak curee. Am J Obstet Gynecol 1991; 165:1287-9. 3. Johnson CA. Making sense of dysfunconal uterine bleeding. Am Fam Physician 1991; 44:149-57 Management of Acute Abnormal Uterine Bleeding in Nonpregnant Reproducve-Aged Women Inial evaluaon of the paent with acute abnormal uterine bleeding should include a prompt assessment for signs of hypovolemia and potenal hemodynamic instability. The eologies of acute abnormal uterine bleeding should be classified using the PALM–COEIN system. Medical management : Opons include intravenous conjugated equine estrogen, mul-dose regimens of combined oral contracepves or oral progesns, and tranexamic acid. Decisions should be based on the paent’s medical history and contraindicaons to therapies. Surgical management should be considered for paents who are not clinically stable, are not suitable for medical management, or have failed to respond appropriately to medical management. The choice of surgical management should be based on the paent’s underlying medical condions, underlying pathology, and desire for future fer3lity. Once the acute bleeding episode has been controlled, transioning the paent to long-term maintenance therapy is recommended. Management of acute abnormal uterine bleeding in nonpregnant reproducve-aged women. Commiee Opinion No. 557. American College of Obstetricians and Gynecologists. Obstet Gynecol 2013;121:891–6. Management of Acute Abnormal Uterine Bleeding in Nonpregnant Reproducve-Aged Women Acute AUB refers to an episode of heavy bleeding that, in the opinion of the clinician, is of sufficient quanty to require immediate intervenon to prevent further blood loss. Acute AUB may occur spontaneously or within the context of chronic AUB (abnormal uterine bleeding present for most of the previous 6 months). The general process for evaluang paents who present with acute AUB can be approached in three stages: 1) assessing rapidly the clinical picture to determine paent acuity, 2) determining most likely eology of the bleeding, and 3) choosing the most appropriate treatment for the paent. Management of acute abnormal uterine bleeding in nonpregnant reproducve-aged women. Commiee Opinion No. 557. American College of Obstetricians and Gynecologists. Obstet Gynecol 2013;121:891–6. Management of Acute Abnormal Uterine Bleeding in Nonpregnant Reproducve-Aged Women Once the acute episode of bleeding has been controlled, mulple treatment opons are available for long-term treatment of chronic AUB. Effecve medical therapies include the levonorgestrel intrauterine system, OCs (monthly or extended cycles), progesn therapy (oral or intramuscular), tranexamic acid, and nonsteroidal an-inflammatory drugs (6). If a paent is receiving IV conjugated equine estrogen, the health care provider should add progesn or transion to OCs. Unopposed estrogen should not be used as long-term treatment for chronic AUB. Paents with known or suspected bleeding disorders may respond to the hormonal and nonhormonal management opons listed earlier in this secon. Consultaon with a hematologist is recommended Effec3ve medical therapies include: for these paents, especially if bleeding is difficult to control or the gynecologist is unfamiliar with the other opons for medical management. the levonorgestrel intrauterine system, Desmopressin may help treat acute AUB in paents with von Willebrand disease if the paent is known to respond to that agent. It may be administered by OCs (monthly or extended cycles), intranasal inhalaon, intravenously, or subcutaneously. This agent must be used with cauon because of the risks of fluid retenon and hyponatremia and should not be administered to paents with progesn therapy (oral or intramuscular), tranexamic massive hemorrhage who are receiving IV fluid resuscitaon because of issues with fluid overload (15). acid, Recombinant factor VIII and von Willebrand factor also are available and may be required to control severe hemorrhage (5). Other factor deficiencies may need factor-specific replacement. and nonsteroidal an-inflammatory drugs Paents with bleeding disorders or platelet funcon abnormalies should avoid nonsteroidal aninflammatory drugs because of their effect on platelet aggregaon and their interacon with drugs that might affect liver funcon and the producon of clong factors (17). Management of acute abnormal uterine bleeding in nonpregnant reproducve-aged women. Commiee Opinion No. 557. American College of Obstetricians and Gynecologists. Obstet Gynecol 2013;121:891–6. ABNORMAL UTERINE BLEEDINGS - CONCENSUS BRIJUNI 2015 2015 USA Conclusions and Recommendaons Based on the available evidence and expert opinion, the American College of Obstetricians and Gynecologists’ Commiee on Gynecologic Pracce makes the following conclusions and recommendaons: The eologies of acute AUB should be classified based on the PALM–COEIN system: Polyp, Adenomyosis, Leiomyoma, Malignancy and hyperplasia, Coagulopathy, Ovulatory dysfuncon, Endometrial, Iatrogenic, and Not otherwise classified. Medical management should be the inial treatment for most paents, if clinically appropriate. Opons include IV conjugated equine estrogen, mul-dose regimens
Load more

Recommended publications
  • Chapter 2 PET and SPECT Imaging of Steroid Hormone Receptors
    University of Groningen PET imaging of brain sex steroid hormone receptors and the role of estrogen in depression Khayum, Mohamed Abdul IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Publication date: 2015 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Khayum, M. A. (2015). PET imaging of brain sex steroid hormone receptors and the role of estrogen in depression. University of Groningen. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 27-09-2021 Chapter 2 PET and SPECT Imaging of Steroid Hormone Receptors Khayum MA, Doorduin J, Glaudemans AWJM, Dierckx RAJO, de Vries EFJ. PET and SPECT of Neurobiological Systems, R.A.J.O. Dierckx et al. (eds.) DOI 10.1007/978-3-642-42014-6_14, © Springer-Verlag Berlin Heidelberg 2014 Chapter 2 Abstract Steroid hormones like estrogens, progestins, androgens and corticosteroids are involved in normal brain function.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • 2011/097571 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau „ (10) International Publication Number (43) International Publication Date \i\ 11 August 2011 (11.08.2011) 2011/097571 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 38/22 (2006.01) A61P 11/06 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/573 (2006.01) A61P 11/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61P 29/00 (2006.01) A61P 37/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US201 1/023917 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 7 February 201 1 (07.02.201 1) NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (25) Filing Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/302,325 8 February 2010 (08.02.2010) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, 13/021,950 7 February 201 1 (07.02.201 1) US ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (71) Applicant (for all designated States except US): EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, PRAIRIE PHARMACEUTICALS, LLC [US/US]; LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, 1041 1 Motor City Drive, Suite 750, Bethesda, MD 20817 SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (US).
    [Show full text]
  • Annex 2 Composition of Oral and Injectable Estrogen–Progestogen Contraceptives
    ANNEX 2 COMPOSITION OF ORAL AND INJECTABLE ESTROGEN–PROGESTOGEN CONTRACEPTIVES Annex 2 lists the composition of brands of estrogen–progestogen preparations used in combined injectables (Table 1), combined oral (Table 2) and phasic oral (Table 3) contraceptives. The countries in which these formulations are used are noted. Are listed only those brands for which availability was reported. The source of these tables is the International Planned Parenthood Foundation (IPPF). Data have been taken from the IPPF 2002 website [http://contraceptive.ippf.org] at the time of the monograph meeting (June 2005). This online site is regularly updated. Table 1. Combined injectables Brand name Composition Countries of availability Acefil Dihydroxyprogesterone acetophenide 150 mg Paraguay + estradiol enanthate 10 mg Agurin Dihydroxyprogesterone acetophenide 150 mg Chile + estradiol enanthate 10 mg Anafertin Dihydroxyprogesterone acetophenide 75 mg El Salvador, Mexico + estradiol enanthate 5 mg Ciclofem Medroxyprogesterone acetate 25 mg Guatemala + estradiol cypionate 5 mg Ciclofemina Medroxyprogesterone acetate 25 mg El Salvador + estradiol cypionate 5 mg Ciclomes Dihydroxyprogesterone acetophenide 150 mg Paraguay + estradiol enanthate 10 mg Ciclovular Dihydroxyprogesterone acetophenide 150 mg Brazil + estradiol enanthate 10 mg Clinomin Dihydroxyprogesterone acetophenide 150 mg Paraguay + estradiol enanthate 10 mg Cyclofem Medroxyprogesterone acetate 25 mg Chile, Indonesia, Malaysia, Mexico, + estradiol cypionate 5 mg Panama, Zimbabwe Cyclofemina Medroxyprogesterone
    [Show full text]
  • Inhibitors, Agonists, Screening Libraries
    www.MedChemExpress.com Inhibitors, Agonists, Screening Libraries Immunology Targeted Inhibitors Inhibitors Inhibitor Cocktails Compound Screening Libraries Disease Related Products Vitamin D Related Products Natural Products GPCR/G Protein Antibody-Drug Conjugate Related Products Epigenetics Cell Cycle/DNA Damage Cancer Cell Autophagy Stem Cells/Wnt Targeted Signaling 1)NJ% Inhibitors Pathways PI3K/Akt/mTOR MAPK/ERK Pathway Protein Tyrosine Kinase TGF-beta/Smad Antibody-Drug Compound Conjugates Screening Libraries MedChemExpress Contents About Us 2 About Us Overview of MCE MedChemExpress (MCE) offers a wide range of high quality research chemicals and biochemicals including novel life-science reagents, reference compounds, APIs and natural compounds for laboratory and scientific use. MCE has 3 Inhibitors knowledgeable and friendly customer service and technical support teams with years of experience in the life science industry. MCE will be a competent and trustworthy partner for your research and scientific projects. 5 Inhibitor Cocktails Quality Product quality is the key to our success and we take pride in offering only the highest-grade products. Product identity, quality, purity and activity are assured by our robust quality control and assurance polices, programs and 6 Screening Libraries procedures. We perform thorough analytical testing - including HNMR, LC-MS and HPLC - stability testing and activity assays on our products and the results from these tests are available to clients. 7 Disease Related Products Experience Vitamin D Related Products Our chemists are highly experienced in molecular synthesis and the preparation of large quantities of structurally diverse and synthetically challenging molecules. We work with clients that have widely different needs and we have 8 Natural Products been very successful in meeting such needs.
    [Show full text]
  • Progestin - Wikipedia, the Free Encyclopedia
    Progestin - Wikipedia, the free encyclopedia http://en.wikipedia.org/wiki/Progestin From Wikipedia, the free encyclopedia A progestin is a synthetic[1] progestogen that has progestinic effects similar to progesterone. [2] The two most common uses of progestins are for hormonal contraception (either alone or with an estrogen), and to prevent endometrial hyperplasia from unopposed estrogen in hormone replacement therapy. Progestins are also used to treat secondary amenorrhea, dysfunctional uterine bleeding and endometriosis, and as palliative treatment of endometrial cancer, renal cell carcinoma, breast cancer, and prostate cancer. High-dose megestrol acetate is used to treat anorexia, cachexia, and AIDS-related wasting. Progesterone (or sometimes the progestin dydrogesterone or 17α-hydroxyprogesterone caproate) is used for luteal support in IVF protocols, questionably for treatment of recurrent pregnancy loss, and for prevention of preterm birth in pregnant women with a history of at least one spontaneous preterm birth.[3] They are also used in judicial chemical castration of sex offenders as well as a treatment options for those suffering from paraphilia. Co-inventor Luis E. Miramontes's signed laboratory notebook. October 15, 1951 1 History 2 Examples 3 Methods of progestin-based contraception 4 See also 5 References The recognition of progesterone's ability to suppress ovulation during pregnancy spawned a search for a similar hormone that could bypass the problems associated with administering progesterone (low bioavailability when administered
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • WO 2012/055840 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date _ . _ . 3 May 2012 (03.05.2012) WO 2012/055840 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/00 (2006.01) A61P 5/30 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/565 (2006.01) A61P 5/34 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 31/57 (2006.01) A61P 15/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, A61K 33/30 (2006.01) A61P 15/18 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (21) International Application Number: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, PCT/EP201 1/068596 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (22) International Filing Date: NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, 25 October 201 1 (25.10.201 1) RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (25) Filing Language: English ZM, ZW. (26) Publication Langi English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/407,570 28 October 2010 (28.10.2010) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, (71) Applicant (for all designated States except US): BAYER RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, PHARMA AKTIENGESELLSCHAFT [DE/DE]; DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, Muller Strasse 178, 13353 Berlin (DE).
    [Show full text]
  • Nuclear Receptors As Drug Targets
    Nuclear Receptors as Drug Targets Edited by Eckhard Ottow and Hilmar Weinmann WILEY- VCH WILEY-VCH Verlag GmbH & Co. KGaA Contents List of Contributors XV Preface XIX A Personal Foreword XXI 1 Nuclear Receptors as Drug Targets: A Historical Perspective of Modern Drug Discovery 1 Eckhard Ottow and Hilmar Weinmann 1.1 Introduction 1 1.2 Short Historical Overview on Nuclear Receptors in Pharmacological Research and Drug Discovery 1 1.2.1 Glucocorticoid Receptor Research 2 1.2.2 Estrogen Receptor Research 3 1.2.3 Progesterone Receptor Research 4 1.2.4 Other Receptor Research 6 1.3 Recent Progress in Nuclear Receptor Drug Discovery 9 1.3.1 SERMs 9 1.3.2 Selective GR Modulators 11 1.3.3 Other Modulator Efforts: PR, MR, AR, PPAR, FXR and LXR 12 1.4 Modern Methods and Technologies in Nuclear Receptor Drug Discovery 13 1.4.1 Cofactor Interaction Screening 14 1.4.2 Microarray Technology and Gene Expression Profiling 14 1.4.3 Novel Computational Methods 15 1.4.4 Structural Biology 15 1.5 Summary and Future Developments 16 References 17 2 Targeting the Nuclear Receptor-Cofactor Interaction 25 Belen Vaz, Sabine Mocklinghoff, and Luc Brunsveld 2.1 Introduction 25 2.2 Evaluation of the Nuclear Receptor-Cofactor Interaction as a Drug Target 28 Nuclear Receptors as Drug Targets. Edited by Eckhard Ottow and Hilmar Weinmann Copyright © 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim ISBN: 978-3-527-31872-8 VI Contents 2.2.1 Evaluation of the ER-Coactivator Interaction 29 2.2.2 Evaluation of the AR-Coactivator Interaction 31 2.3 Inhibitors of the Nuclear Receptor-Cofactor Interaction 33 2.3.1 Phage Display Peptides 33 2.3.2 Nonnatural Cyclic Peptides 34 2.3.3 Small Molecules 37 2.4 Perspectives 39 References 40 3 Untangling the Estrogen Receptor Web: Tools to Selectively Study Estrogen-Binding Receptors 47 Ross V.
    [Show full text]
  • Literature Review of Organic Chemicals of Emerging Environmental Concern in Use in Auckland December TR 2008/028
    Literature Review of Organic Chemicals of Emerging Environmental Concern in Use in Auckland December TR 2008/028 Auckland Regional Council Technical Report No.028 December 2008 ISSN 1179-0504 (Print) ISSN 1179-0512 (Online) ISBN 978-1-877483-69-1 Technical Report, first edition Reviewed by: Approved for ARC publication by: Name: Judy-Ann Ansen Name: Paul Metcalf Position: Team Leader Position: Group Manager Stormwater Action Team Environmental Programmes Organisation: Auckland Regional Council Organisation: Auckland Regional Council Date: 1 November 2008 Date: 1 October 2009 Recommended Citation: AHERNS, M., 2008. Review of Organic Chemicals of Potential Environmental Concern in Use in Auckland. Prepared by NIWA for Auckland Regional Council. Auckland Regional Council Technical Report 2008/028. © 2008 Auckland Regional Council This publication is provided strictly subject to Auckland Regional Council's (ARC) copyright and other intellectual property rights (if any) in the publication. Users of the publication may only access, reproduce and use the publication, in a secure digital medium or hard copy, for responsible genuine non-commercial purposes relating to personal, public service or educational purposes, provided that the publication is only ever accurately reproduced and proper attribution of its source, publication date and authorship is attached to any use or reproduction. This publication must not be used in any way for any commercial purpose without the prior written consent of ARC. ARC does not give any warranty whatsoever, including without limitation, as to the availability, accuracy, completeness, currency or reliability of the information or data (including third party data) made available via the publication and expressly disclaim (to the maximum extent permitted in law) all liability for any damage or loss resulting from your use of, or reliance on the publication or the information and data provided via the publication.
    [Show full text]
  • I Regulations
    23.2.2007 EN Official Journal of the European Union L 56/1 I (Acts adopted under the EC Treaty/Euratom Treaty whose publication is obligatory) REGULATIONS COUNCIL REGULATION (EC) No 129/2007 of 12 February 2007 providing for duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation and specified products used for the manufacture of finished pharmaceuticals and amending Annex I to Regulation (EEC) No 2658/87 THE COUNCIL OF THE EUROPEAN UNION, (4) In the course of three such reviews it was concluded that a certain number of additional INNs and intermediates used for production and manufacture of finished pharmaceu- ticals should be granted duty-free treatment, that certain of Having regard to the Treaty establishing the European Commu- these intermediates should be transferred to the list of INNs, nity, and in particular Article 133 thereof, and that the list of specified prefixes and suffixes for salts, esters or hydrates of INNs should be expanded. Having regard to the proposal from the Commission, (5) Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Common Customs Tariff (1) established the Combined Nomenclature Whereas: (CN) and set out the conventional duty rates of the Common Customs Tariff. (1) In the course of the Uruguay Round negotiations, the Community and a number of countries agreed that duty- (6) Regulation (EEC) No 2658/87 should therefore be amended free treatment should be granted to pharmaceutical accordingly, products falling within the Harmonised System (HS) Chapter 30 and HS headings 2936, 2937, 2939 and 2941 as well as to designated pharmaceutical active HAS ADOPTED THIS REGULATION: ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation, specified salts, esters or hydrates of such INNs, and designated inter- Article 1 mediates used for the production and manufacture of finished products.
    [Show full text]
  • Progestagens for Human Use. Exposure and Hazard Assessment for the Aquatic Environment J.P
    Progestagens for human use. Exposure and hazard assessment for the aquatic environment J.P. Besse, J. Garric To cite this version: J.P. Besse, J. Garric. Progestagens for human use. Exposure and hazard assessment for the aquatic environment. Environmental Pollution, Elsevier, 2009, 157 (12), p. 3485 - p. 3494. 10.1016/j.envpol.2009.06.012. hal-00455636 HAL Id: hal-00455636 https://hal.archives-ouvertes.fr/hal-00455636 Submitted on 10 Feb 2010 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Environmental Pollution, vol. 157, n° 12, doi : 10.1016/j.envpol.2009.06.012 1 Progestagens for human use, exposure and hazard assessment for 2 the aquatic environment 3 4 5 6 Reviewed version of manuscript ENVPOL-D-09-00080R1. 7 The abstract of this paper was evaluated and approved by Dr Wiegand. 8 9 10 Authors 11 12 Jean-Philippe BESSE a* 13 Jeanne GARRIC a** 14 15 a Unité Biologie des écosystèmes aquatiques. Laboratoire d’écotoxicologie, 16 Cemagref, 3bis quai Chauveau CP 220 69336 Lyon cedex 09, France 17 Tel.: +33 472208902 18 19 * first author 20 ** corresponding author. E-mail address: [email protected] 21 22 23 Capsule: 24 Gestagens exposure and hazard assessment for the aquatic environment.
    [Show full text]